Pulse Biosciences Doubles Down on Thyroid Nodule Study with 100-Patient Enrollment — Pulse Biosciences, Inc.

Event summary

Pulse Biosciences completed enrollment in the PRECISE-BTN study, doubling the original 50-patient target to 100 patients across three U.S. clinical sites.
The first patient enrolled completed the final 12-month follow-up visit in August 2026 at Sarasota Memorial Health Care System.
The study evaluates the safety and effectiveness of the nPulse™ Vybrance™ Percutaneous Electrode System for treating symptomatic benign thyroid nodules.
Preliminary data from the study is expected to be presented at an upcoming medical society conference, with full data anticipated upon completion of the 12-month follow-up for all patients.

The big picture

Pulse Biosciences' completion of the PRECISE-BTN study enrollment marks a significant step in validating its nPulse™ technology for a new indication. The doubling of the study size to 100 patients suggests strong confidence in the technology's potential and could pave the way for broader applications in the medical device sector. The study's outcomes will be closely watched as they could influence regulatory decisions and market adoption of the nPulse™ Vybrance™ system.

What we're watching

Clinical Efficacy: How the preliminary and full data from the PRECISE-BTN study will impact the perceived effectiveness of the nPulse™ Vybrance™ system in treating benign thyroid nodules.
Regulatory Pathway: Whether the positive outcomes from the study will accelerate regulatory approvals for the nPulse™ Vybrance™ system.
Market Expansion: The pace at which Pulse Biosciences can expand the use of its nPulse technology into other medical markets, such as atrial fibrillation and surgical soft tissue ablation.